IPCA Laboratories logo

IPCA Laboratories share news, announcements and annual reports

NSE: IPCALABBSE: 524494Pharmaceuticals & BiotechnologyMid Cap

IPCA Laboratories Limited · Face value ₹1 · Listed May 1994 on BSE, Feb 1995 on NSE
Last close ₹1,927.80up ₹1.60 (0.08%)BSE ₹1,927.70

Share price at the NSE close on 30 Oct 2026. Previous close ₹1,926.20.

30 Oct: open ₹1,945.20, high ₹1,964.90, low ₹1,921.40

52-week range of traded prices to 30 Oct 2026
₹1,268.00Low, 31 Oct 2025₹2,038.00High, 18 Sep 2026
Market cap
₹48,909 Cr229th largest listed
P/E
37.34
P/B
6.07
Dividend yield
0.31%
ROE
17.4%
ROCE
17.6%
Debt to equity
0.07
Volume, NSE
2,53,52767.6% delivered

IPCA Laboratories share news and announcements

772 announcements, routine notices left out, newest first. Page 15 of 16.

  1. Feb 2009

    • 25 Feb · Buyback of Shares

      Imperial Corporate Finance & Services Pvt. Ltd. has submitted to the Exchange a copy of fortnightly reporting with regards to Buy-back of Equity Shares by Ipca Laboratories Ltd from the "Open Market" purchase through Stock Exchanges in compliance with Regulation 15(i) of the SEBI (Buy Back of Securities) Regulations, 1998, published in the newspaper on February 23, 2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.

    • 20 Feb · Extinguishment

      Ipca Laboratories Ltd. has informed the Exchange that 4,146 (Four Thousand One Hundred and Forty Six) equity shares of the Company which were purchased in the Company's buy-back program through open market purchase have been extinguished. The details of the paid-up equity share capital of the Company Pre and Post Extinguishment of Shares shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.

    • 11 Feb · Extinguishment

      Ipca Laboratories Ltd. has informed the Exchange that 16,637 (Sixteen Thousand Six Hundred and Thirty Seven) equity shares of the Company which were purchased in the Company's buy-back program through open market purchase have been extinguished. The details of the paid-up equity share capital of the Company Pre and Post Extinguishment of Shares shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.

    • 10 Feb · Buyback of Shares

      Imperial Corporate Finance & Services Pvt. Ltd. has submitted to the Exchange a copy of Buy-back of Equity Shares by Ipca Laboratories Ltd from the "Open Market" purchase through Stock Exchanges in compliance with Regulation 15(i) of the SEBI (Buy Back of Securities) Regulations, 1998, published in the newspaper on February 08, 2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.

    • 9 Feb · Disclosure

      Ipca Laboratories Ltd. has informed the Exchange that "The Company has been informed by the promoters that they have pledged in aggregate 41,28,658 equity shares held by them in the Company. The pledged shares represent 16.41% of the Company's paid-up equity share capital". Further, the company has submitted to the Exchange Regulation 8A (4) of SEBI ( Substantial Acquisition of Shares and Takeovers) (Amendment) Regulations, 2009. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.

    • 3 Feb · Extinguishment

      Ipca Laboratories Ltd. has submitted to the Exchange Buy-back of equity shares of the Company from open market purchase - Monthly report/Certificate for the month of January 2009. Total Extinguishment for the month of January 2009 : 90939 shares. The copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.

    • 2 Feb · Extinguishment

      Ipca Laboratories Ltd. has informed the Exchange that 66,491 (Sixty Six Thousand Four Hundred and Ninety One) equity shares of the Company which were purchased in the Company's buy-back program through open market purchase have been extinguished. The details of the paid-up equity share capital of the Company Pre and Post Extinguishment of Shares shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.

  2. Jan 2009

    • 27 Jan · Buyback of Shares

      Imperial Corporate Finance & Services Pvt. Ltd. has submitted to the Exchange a copy of Buy-back of Equity Shares by Ipca Laboratories Ltd from the "Open Market" purchase through Stock Exchanges in compliance with Regulation 15(i) of the SEBI (Buy Back of Securities) Regulations, 1998, published in the newspaper on January 24, 2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.

    • 23 Jan · Extinguishment

      Ipca Laboratories Ltd. has informed the Exchange that 16,910 (Sixteen Thousand Nine Hundred and Ten) equity shares of the Company which were purchased in the Company's buy-back program through open market purchase have been extinguished. The details of the paid-up equity share capital of the Company Pre and Post Extinguishment of Shares shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.

    • 22 Jan · Business

      Ipca Laboratories Ltd. has informed the Exchange regarding a press release titled "Ipca- Financial Result". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.

    • 22 Jan · Dividend

      Ipca Laboratories Ltd. has informed the Exchange that the Board at its meeting held on January 22, 2009 has declared an 2nd interim dividend of 30% (Rs. 3/- per share) for the financial year 2008-09.

    • 15 Jan · Extinguishment

      Ipca Laboratories Ltd. has informed the Exchange that 7,538 (Seven Thousand Five Hundred and Thirty Eight) equity shares of the Company which were purchased in the Company's buy-back program through open market purchase have been extinguished. The details of the paid-up equity share capital of the Company Pre and Post Extinguishment of Shares shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.

    • 9 Jan · Buyback of Shares

      Imperial Corporate Finance & Services Pvt. Ltd. has submitted to the Exchange a copy of Buy-back of Equity Shares by Ipca Laboratories Ltd from the "Open Market" purchase through Stock Exchanges in compliance with Regulation 15(i) of the SEBI (Buy Back of Securities) Regulations, 1998, published in the newspaper on January 09, 2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.

    • 9 Jan · Board meeting

      Inter-alia, to consider the following: (1) Unaudited Financial Results for 3rd quarter and nine months ended December 31, 2008; and (2) 2nd Interim Dividend for the financial year 2008-09. Further the Company has decided to fix January 28, 2009 as the 'Record Date' for the Members entitlement of 2nd interim dividend for the financial year 2008-09 that may be declared at the said Board Meeting.

    • 6 Jan · Extinguishment

      Ipca Laboratories Ltd. has submitted to the Exchange Buy-back of equity shares of the Company from open market purchase - Monthly report / Certificate for the month of December 2008. The copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.

  3. Dec 2008

    • 29 Dec · Updates

      Ipca Laboratories Ltd. has informed the Exchange that Life Insurance Corporation of India (LIC) has subscribed to Company's 500, 12.75% Secured, Redeemable Non Convertible Debentures of the face value of Rs. 1 million each amounting to Rs. 500 millions. These debentures will be redeemed in 3 equal annual installments at the end of 3rd, 4th, and 5th year from the date of subscription. Further details of Subscription to Non Convertible Debentures of Rs. 500 millions and CRISIL rating for ongoing Debt Programme shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.

    • 26 Dec · Extinguishment

      Ipca Laboratories Ltd. has informed the Exchange that 11,427 (Eleven Thousand Four Hundred and Twenty Seven) equity shares of the Company which were purchased in the Company's buy-back program through open market purchase have been extinguished. The details of the paid-up equity share capital of the Company Pre and Post Extinguishment of Shares shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.

    • 26 Dec · Buyback of Shares

      Imperial Corporate Finance & Services Pvt. Ltd. has submitted to the Exchange a copy of Buy-back of Equity Shares by Ipca Laboratories Ltd from the "Open Market" purchase through Stock Exchanges in compliance with Regulation 15(i) of the SEBI (Buy Back of Securities) Regulations, 1998, published in the newspaper on December 25, 2008. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.

    • 11 Dec · Corrigendum

      Imperial Corporate Finance & Services Pvt Ltd. has submitted to the Exchange a copy of the corrigendum released in the news papers on December 09, 2008 in respect of Buy-back of Equity Shares by Ipca Laboratories Ltd. using "Open Market" purchase through Stock Exchanges in compliance with Securities and Exchange Board of India (Buy Back of Securities) Regulations, 1998. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements) For more details click here.

  4. Nov 2008

    • 25 Nov · Public Announcement - Buyback of Shares

      Imperial Corporate Finance & Services Pvt Ltd. has informed the Exchange regarding Public Announcement ("Announcement") dated November 24, 2008 made pursuant to the provisions of Regulation 8(1) read with Regulation 15(c) of the Securities and Exchange Board of India (Buy Back of Securities) Regulations, 1998 for the time being in force including any statutory modifications and amendments from time to time ("Buy Back Regulations") and contains the disclosures as specified in Schedule II to these Buy Back Regulations. Details of the Buyback Offer and Offer Price: IPCA Laboratories Ltd (the "Company/Ipca") hereby announces the buyback of its own fully paid-up equity shares of the face value Rs. 10/- each ("Equity Shares") from the existing owners of Equity Shares (the "Buy-back") of the Company from the open market through stock exchanges using the nationwide electronic trading facilities of the Bombay Stock Exchange Limited ("BSE") and/or the National Stock Exchange of India Limited ("NSE") (together "the Stock Exchanges") in accordance with the provisions of Section 77A, 77AA, 77B and all other applicable provisions, if any, of The Companies Act ,1956 ("the Act") and the Securities and Exchange Board of India (Buyback of Securities) Regulations, 1998 ("the Buy Back Regulations"), as amended to date and the relevant provisions of the Memorandum of Association and Articles of Association of the Company, subject to such approval(s) as may be necessary, from time to time, from statutory authorities including but not limited to Securities and Exchange Board of India, Stock Exchanges, Reserve Bank of India, etc as required, at a maximum price not exceeding Rs. 600/- per Equity Share (" Maximum Offer Price") payable in cash, for an aggregate amount up to Rs. 60.00 crores ("Maximum Offer Size"). The Date of Opening of Buy-back is December 03, 2008 and the Last Date for the Buy-back is November 10, 2009 (i.e. within 12 months from the date of resolution passed by the Board of Directors of the Company at its meeting held on November 11, 2008) or when the Company completes the Buy-back to the extent of Rs. 60.00 Crores or such earlier date as may be decided by the Board of Directors at any time (by giving appropriate notice of such earlier date, if any) which ever is earlier. A copy of the Public Announcement-Buyback of Shares shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.

    • 12 Nov · Public Notice - Buy Back of Equity Shares

      Imperial Corporate Finance & Services Pvt. Ltd. has, as manager to the Buy-back of Equity Shares by IPCA Laboratories Ltd using "Open Market" purchase through Stock Exchanges in compliance with Securities and Exchange Board of India (Buy Back of Securities) Regulations, 1998, informed the Exchange that M/s IPCA Laboratories Limited has issued a Public Notice (PN) in the newspapers on November 12, 2008. A copy of the public notice shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.

    • 11 Nov · Management

      Ipca Laboratories Ltd. has informed the Exchange that at the meeting of the Board of Directors of the Company held on November 11, 2008, Mr. Pranay Godha, son of Mr. Premchand Godha and who is currently President - APIs and Generics of the Company has been appointed as an Additional Director of the Company and designated as Wholetime Executive Director. The details of the composition of the Board of Directors of the Company shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.

    • 11 Nov · Buyback of Shares

      Ipca Laboratories Ltd. has submitted to the Exchange a copy of the resolution passed at the meeting of the Board of Directors of the Company held on November 11, 2008 regarding buy back of the Company's fully paid up equity shares of the face value of Rs. 10/- each from the open market through Stock Exchanges using electronic trading facilities of The Bombay Stock Exchange Ltd. (BSE) and National Stock Exchange of India Ltd. (NSE) at the price not exceeding Rs. 600/- per share and for a maximum aggregate outlay amount of upto Rs. 60 crores (Rupees Sixty Crores Only). A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.

    • 11 Nov · Disclosure

      Ipca Laboratories Ltd. has informed the Exchange that the Compensation Committee of the Board of Directors in their meeting held on November 11, 2008 have granted 57,000 (Fifty Seven Thousand Only) options under Ipca Laboratories Ltd. - Employees Stock Option Scheme - 2006 (ESOS) to selected Employees of the Company. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.

    • 11 Nov · Buy back / Others

      Ipca Laboratories Ltd. has informed the Exchange vide its letter dated November 11, 2008, that "At the meeting of the Compensation / Remuneration Committee of the Board and that of Board of Directors of the Company held today, inter-alia, following decisions were taken: (1). Appointment of Mr. Pranay Godha, son of Mr. Premchand Godha, Managing Director, who is currently President APIs and Generics of the Company as the Additional Director designated as Whole-time Executive Director and remuneration payable to him; (2). Allotment of 57,000 options to selected permanent employees of the Company under Ipca Laboratories Ltd. Employees Stock Option Scheme (ESOS). Each option granted gives a right but not an obligation to the Option Grantee to apply for 1 fully paid equity share of Rs. 10/- each of the Company at a price of Rs. 315/- (Rupees Three Hundred and Fifteen Only) per share over a period of 4 years; and (3). Subject to necessary consents and applicable statutory provisions, buy back of Company's own fully paid-up equity shares of Rs.10/- each from the open market using electronic trading facilities of the Stock Exchanges with outlay of maximum amount of Rs. 60 crores representing less than 10% of the Company's paid-up equity share capital and free resources at a maximum price of not over Rs. 600/- per share".

    • 4 Nov · Disclosure

      Ipca Laboratories Ltd. has submitted to the Exchange disclosure in Form D in respect of equity shares of the Company allotted to Directors / Officers of the Company under Ipca Laboratories Limited - Employee Stock Option Scheme 2006 (ESOS), pursuant to Regulation 13(6) of the SEBI (Prohibition of Insider Trading) Regulation, 1992. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.

    • 3 Nov · Allotment of Equity Shares

      Ipca Laboratories Ltd. has informed the Exchange that at the meeting of the Board of Directors of the Company held on October 31, 2008, 1,03,250 equity shares of Rs. 10/- each of the Company have been allotted as under : 1) 81,000 fully paid-up equity shares of Rs. 10/- each of the Company @ Rs. 200/- per equity share upon exercise of options by allottees to whom options were granted on September 23, 2006 under Ipca Laboratories Limited - Employee Stock Option Scheme 2006 (ESOS) and; 2) 22,250 fully paid-up equity shares of Rs.10/- each of the Company @ Rs.315/- per equity share upon exercise of options by allottees to whom options were granted on October 29, 2007 pursuant to Ipca Laboratories Limited - Employee Stock Option Scheme 2006 (ESOS). The equity shares now allotted would rank pari-passu in all respect with the existing paid-up equity share capital of the company. With these allotments, the paid up equity share capital of the company is now increased to Rs. 25,19,20,000/- divided into 2,51,92,000 equity shares of Rs. 10/- each.

    • 3 Nov · Management

      Ipca Laboratories Ltd. has informed the Exchange that at the meeting of the Board of Directors of the Company held on October 31, 2008 the resignation of Mr. Thembalath Ramachandran from the Board of Directors of the Company, who has resigned his directorship due to his business/ professional pre-occupation, has been accepted. The revised composition of the Board of Directors of the Company now is as under : 1) Mr. R.S. Hugar : Chairman. 2) Mr. Premchand Godha : Managing Director. 3) Mr. M.R. Chandurkar : Director. 4) Mr. A.K. Jain : Executive Director. 5) Mr. Babulal Jain : Director. 6) Mr. V.A. Gore : Director. 7) Dr. V.V. Subba Rao : Director.

    • 1 Nov · Board meeting

      Inter-alia, to consider the following: (1) Buy back of own equity shares of the Company; and (2) Further grant of options to selected permanent employees of the Company under Ipca Laboratories Ltd - Employees Stock Option Scheme-2006 (ESOS) as sanctioned by the shareholders at the Annual General Meeting of the Company held on July 28, 2006 (as amended from time to time).

  5. Oct 2008

    • 31 Oct · Dividend

      Ipca Laboratories Ltd. has informed the Exchange that the Board of Directors at their meeting held on October 31, 2008 has declared an Interim dividend of 40% for the financial year 2008-09.

    • 31 Oct · Business

      Ipca Laboratories Ltd. has informed the Exchange regarding a press release titled "Ipca- Financial Result". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.

    • 22 Oct · Board meeting

      Inter-alia, to consider the following: (1) Allotment of equity shares on exercise of options under Ipca Laboratories Ltd. - Employees Stock Option Scheme - 2006 (ESOS). (2) Unaudited Financial Results for the quarter and half year ended September 30, 2008; and (3) Interim Dividend for the financial year 2008-09. Further the Company has decided to fix November 10, 2008 as the 'Record Date' for the Members entitlement of interim dividend for the financial year 2008-09 that may be declared at the said Board Meeting.

    • 13 Oct · Business

      Ipca Laboratories Ltd. has informed the Exchange regarding a press release dated October 13, 2008, titled "IPCA-Heritage Alliance Introduces Propranolol Tablets in the U.S.Market". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.

  6. Jul 2008

    • 25 Jul · Business

      Ipca Laboratories Ltd. has informed the Exchange regarding a press release dated July 25, 2008, titled "Q1 Financial Results". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.

    • 16 Jul · Board meeting

      Meeting on 25 Jul 2008: “Unaudited Financial Results for the Qtr ended June 30, 2008”

    • 11 Jul · Disclosure

      Ipca Laboratories Ltd. has informed the Exchange that Company have received a disclosure pursuant to Regulation 13(3) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 1992 in Form C from HDFC Mutual Fund, Mumbai giving the details of acquisition of 2% or more shares of the Company as on July 07, 2008. Further the Company has submitted a copy of Regulation 7(3) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 1997 in response to above disclosure made by HDFC Mutual Fund. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.

  7. Jun 2008

    • 17 Jun · Updates

      Ipca Laboratories Ltd. has informed the Exchange that "IPCA-Ranbaxy Alliance Receive U.S. FDA Marketing Approval for Metoclopramide Tablets". The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.

    • 4 Jun · Updates

      Ipca Laboratories Ltd. has informed the Exchange that "IPCA Receive U.S.FDA Approval for Propranolol Hydrochloride Tablets". The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.

  8. May 2008

    • 30 May · Meeting

      Ipca Laboratories Ltd. has informed the Exchange that the Annual General Meeting of the Company will be held on July 25, 2008. The Company has further informed the Exchange that the Register of Members and Share Transfer Books of the Company will remain closed from July 16, 2008 to July 25, 2008, both days inclusive for the purpose of Annual General Meeting and the entitlement of final dividend @ Rs.4.50 per share (45%).

    • 29 May · Business

      Ipca Laboratories Ltd. has informed the Exchange regarding a press release dated May 29, 2008, titled "Ipca- Financial Result". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.

    • 29 May · Dividend

      Ipca Laboratories Ltd. has informed the Exchange that the Board of Directors of the Company at its meeting held on May 29, 2008 has recommended a final dividend of Rs.4.50 per share (45%) for the financial year 2007-08. Together with the interim dividend of Rs.3.50 per share (35%) already declared and paid, the total Dividend for the financial year amounts to Rs.8/- per share (80%).

    • 20 May · Board meeting

      Inter alia, to consider: (1) The Audited Financial Results for the financial year ended March 31, 2008 and. (2) Recommendation of final dividend for financial year ended March 31, 2008.

  9. Apr 2008

    • 24 Apr · Updates

      Ipca Laboratories Ltd. has informed the Exchange that : "Ipca Laboratories Limited has received approval for its Anti-malarial finished product formulation - Artesunate + Amodiaquine co-blister under WHO's Prequalification Programme. The product is now listed in the WHO Pre-qualification product list dated 23rd April, 2007. IPCA is the 2nd Company in the World to have pre-qualification for the product. The Pre-qualification programme was created by the World Health Organization in 2001. It aims to increase access to priority medicinal products that meet unified standards of acceptable quality, safety and efficacy, currently focusing on those medicines used for treatment of diseases such as Malaria. The list of prequalified medicinal products is used principally by United Nations agencies including UNAIDS and UNICEF - to guide their procurement decisions. But the list has become a vital tool for any agency or organizations involved in bulk purchasing of medicines, be this at country level or at international level, as demonstrated by the Global Fund to fight diseases such as Malaria."

    • 24 Apr · Rating

      Ipca Laboratories Ltd. has informed the Exchange that : "CRISIL has assigned its bank loan rating of AA-/ Stable to Company's bank facilities and re-affirmed its rating Pl+ on Company's short term debt programme."

    • 3 Apr · Results

      Ipca Laboratories Ltd. has informed the Exchange that: "It has been decided by the Company to publish its Audited Financial Results for the financial year ended March 31, 2008 on or before June 30, 2008".

  10. Mar 2008

    • 24 Mar · Updates

      Ipca Laboratories Ltd. has informed the Exchange that "The Company's formulations manufacturing plant at Piparia (Silvassa, U.T. of D & NH ) has been inspected and earned the certificate of GMP compliance of a manufacture from Medicines and Healthcare products Regulatory Agency (MHRA-UK). This certification verifies the quality of the manufacturing operation, quality control, and packaging of the formulations manufactured at this plant. This is the first approval received by Piparia (Silvassa) plant. In the past, Company's plant in Kandla (Gujarat) and Athal (Silvassa, U.T. of D&NH) have also been certified with the MHRA-UK approval. Piparia (Silvassa) plant is the third manufacturing plant of the Company to have received such approval".

    • 24 Mar · Updates

      Ipca Laboratories Ltd. has informed the Exchange that at the meeting of the Board of Directors of the Company held on March 21, 2008, Mr Premchand Godha has been re-appointed as the Managing Director of the Company for a further period of 5 years w.e.f. April 01, 2008, subject to the approval of the members at the forthcoming Annual General Meeting of the Company. The term of appointment of Mr M R Chandurkar as the Managing Director of the Company is coming to an end on close of business hours of the Company on March 31, 2008. Mr M R Chandurkar, who will be of 70 years of age on April 5, 2008 has informed to the Company that he would not like to be re-appointed as the Managing Director of the Company. However, he has offered to continue as the Non-whole-time Director on the Board of the Company. Therefore, effective from the close of business hours of the Company on March 31, 2008, the revised composition of the Board of Directors of the Company is as under : Mr R S Hugar - Chairman (Independent Director). Mr Premchand Godha - Managing Director (Promoter Director). Mr M R Chandurkar - Director (Promoter Director). Mr A K Jain - Executive Director (Non Independent/ Professional Director). Mr T Ramachandran - Director (Independent Director). Mr Babulal Jain - Director (Independent Director). Mr V A Gore - Director (Independent Director). Dr VV Subba Rao - Director (Independent Director).

  11. Feb 2008

    • 27 Feb · Updates

      Ipca Laboratories Ltd. has informed the Exchange vides its letter dated February 27, 2008 that "Yesterday evening there was an incidence of fire in one of the section of cold storage warehouse at the Company's formulations manufacturing unit situated at Athol, Silvassa. This fire has damaged the materials stored in the said cold storage part of the warehouse. The extent of damage is being ascertained. However, there is no damage to the other areas of this formulation manufacturing unit other than the said part of the cold storage warehouse and no material disruption in the manufacturing activities of the said unit. All the manufacturing facilities, materials and finished goods of the Company are adequately insured to cover the risk of fire, flood, earthquakes, etc".

  12. Jan 2008

    • 7 Jan · Board meeting

      Inter alia, to take on record the Unaudited Financial Results for the 3rd Quarter and nine months ended December 31,2007.

  13. Nov 2007

    • 28 Nov · Disclosure

      Ipca Laboratories Ltd. has submitted to the Exchange a copy of the disclosure in respect of equity shares of the Company allotted to Directors/ employees under Ipca Laboratories Limited Employment Stock Option Scheme 2006(ESOS), Pursuant to Regulation 13(6) of the SEBI (Prohibition of Insider Trading) Regulation, 1992. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.